What is Pulse Biosciences, Inc.'s market cap?

Pulse Biosciences, Inc. (PLSE) has a market capitalization of $2.3B and trades on NASDAQ.

What is Pulse Biosciences, Inc.'s revenue and profitability?

Pulse Biosciences, Inc. generated $751.0K in trailing twelve-month revenue with a net loss of $74.6M, representing a net margin of -9929.0%. Gross margin stands at -4067.5%, with free cash flow of -$55.5M. These figures are based on the Q1 2026 filing.

Who are Pulse Biosciences, Inc.'s competitors?

Pulse Biosciences, Inc.'s key competitors include AtriCure, Inc., Boston Scientific Corporation, Medtronic plc, and others. These companies compete in similar markets and product categories.

Who does Pulse Biosciences, Inc. partner with?

Pulse Biosciences, Inc.'s notable partners include Ospedale del Mare, Mount Sinai Fuster Heart Hospital.

Where is Pulse Biosciences, Inc. headquartered?

Pulse Biosciences, Inc. is headquartered in United States of America and employs approximately 56 people. It has been publicly traded since 2016.

Pulse Biosciences, Inc.

PLSE

Market cap

$2.27B+129%

Revenue$751.0K—

Net income-$74.6M-23.8%

Free cash flow-$55.5M-37.9%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 4, 2026

Revenue$400.0KBeat by $150.0K EPS-$0.27Beat by $0.05

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$533.3K

EPS estimate-$0.31

Financials

Q1 2026

Income statement

See full

Revenue$401.0K—

Gross profit$31.0K—

Operating income-$19.2M-6.1%

Net income-$18.6M-10.6%

Balance sheet

See full

Cash & equivalents$68.3M-42.7%

Total debt$7.2M-16.6%

Total equity$66.3M-44.0%

Total assets$81.6M-38.8%

Cash flow

See full

Operating cash flow-$14.6M-7.9%

CapEx$33.0K-26.7%

Free cash flow-$14.6M-7.8%

Valuation & ratios

Valuation

See full

Market cap$2.27B+129%

Enterprise value$2.21B+139%

P/S3,021.8×—

Profitability

See full

Operating margin-10,392.1%—

Net margin-9,929%—

FCF margin-7,390%—

Returns & leverage

See full

Return on equity-80.7%+3.1pp

Debt / equity0.1×0.0×

Current ratio7.3×-8.3×

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Abbott$182.00B-17.2%

Medtronic$107.81B-8.5%

Boston Scientific$67.6B-56.8%

Pulse Biosciences, Inc.$2.3B+122%

AtriCure$1.9B+15.1%

Adagio Medical$10.7M-57.1%

Catheter Precision$1.0M-61.7%

By revenue growth

AtriCure+13.9%

Boston Scientific+13.5%

Medtronic+8.4%

Abbott+8.1%

Johnson & Johnson+8.1%

By net margin

Johnson & Johnson21.48%-3.5pp

Boston Scientific17.48%+4.0pp

Medtronic13.2%-0.7pp

Abbott11.65%-20.8pp

AtriCure-5.55%+8.1pp

Pulse Biosciences, Inc.-9,929.03%—

Profile

Pulse Biosciences is a medical technology company that develops and commercializes a proprietary Nano-pulse Stimulation (NPS) technology platform, also known as Nanosecond Pulsed-Field Ablation (nsPFA). The company's core value proposition is a nonthermal energy modality that delivers nanosecond-duration electrical pulses to precisely clear or kill targeted cells while sparing surrounding acellular tissue and nerves. The company is currently focused on applying this technology to the treatment of atrial fibrillation and soft tissue ablation in surgical settings.

Competitive position

A specialized innovator in nanosecond pulsed-field ablation, seeking to disrupt the established thermal ablation market dominated by large medical device incumbents.

GeographiesUnited States, European Union

Customer segmentsSpecialized surgical centers, Hospitals, Electrophysiology clinics

Business modelRazor-and-blade, Medical device manufacturing, IP licensing

SuppliersSpecialized electronic component manufacturers, Medical-grade material suppliers, Contract manufacturers

CustomersAcute care hospitals, Cardiac surgery centers, Specialty medical clinics

CountryUnited States of America

Listed2016

Employees56.0

CEOPaul Arthur LaViolette

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websitepulsebiosciences.com

FilingsSEC EDGAR

Ask your AI about Pulse Biosciences, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pulse Biosciences, Inc.'s market cap?: Pulse Biosciences, Inc. (PLSE) has a market capitalization of $2.3B and trades on NASDAQ.
What is Pulse Biosciences, Inc.'s revenue and profitability?: Pulse Biosciences, Inc. generated $751.0K in trailing twelve-month revenue with a net loss of $74.6M, representing a net margin of -9929.0%. Gross margin stands at -4067.5%, with free cash flow of -$55.5M. These figures are based on the Q1 2026 filing.
Who are Pulse Biosciences, Inc.'s competitors?: Pulse Biosciences, Inc.'s key competitors include AtriCure, Inc., Boston Scientific Corporation, Medtronic plc, and others. These companies compete in similar markets and product categories.
Who does Pulse Biosciences, Inc. partner with?: Pulse Biosciences, Inc.'s notable partners include Ospedale del Mare, Mount Sinai Fuster Heart Hospital.
Where is Pulse Biosciences, Inc. headquartered?: Pulse Biosciences, Inc. is headquartered in United States of America and employs approximately 56 people. It has been publicly traded since 2016.